|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
1999-9-2
|
|
pubmed:abstractText |
The prognosis for gastric cancer remains dismal; novel agents that target specific molecular pathways are needed as adjuvant therapy. Camptothecin (CPT), on inhibitor of topoisomerase I, is effective in the treatment of certain solid tumors; its effects on gastric cancer are largely undefined. The purpose of this study was to (1) characterize the effects of CPT on the growth of a human gastric cancer and (2) assess potential cellular mechanisms responsible for CPT-mediated growth inhibition.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents, Phytogenic,
http://linkedlifedata.com/resource/pubmed/chemical/CDKN1A protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Camptothecin,
http://linkedlifedata.com/resource/pubmed/chemical/Cdkn1a protein, mouse,
http://linkedlifedata.com/resource/pubmed/chemical/Cyclin-Dependent Kinase Inhibitor...,
http://linkedlifedata.com/resource/pubmed/chemical/Cyclins,
http://linkedlifedata.com/resource/pubmed/chemical/Microfilament Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Muscle Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Proto-Oncogene Proteins c-bcl-2,
http://linkedlifedata.com/resource/pubmed/chemical/Tagln protein, mouse,
http://linkedlifedata.com/resource/pubmed/chemical/Tumor Suppressor Protein p53
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Aug
|
|
pubmed:issn |
0039-6060
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
126
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
223-30
|
|
pubmed:dateRevised |
2007-11-14
|
|
pubmed:meshHeading |
pubmed-meshheading:10455888-Adenocarcinoma,
pubmed-meshheading:10455888-Animals,
pubmed-meshheading:10455888-Antineoplastic Agents, Phytogenic,
pubmed-meshheading:10455888-Apoptosis,
pubmed-meshheading:10455888-Camptothecin,
pubmed-meshheading:10455888-Cell Division,
pubmed-meshheading:10455888-Cyclin-Dependent Kinase Inhibitor p21,
pubmed-meshheading:10455888-Cyclins,
pubmed-meshheading:10455888-Humans,
pubmed-meshheading:10455888-Male,
pubmed-meshheading:10455888-Mice,
pubmed-meshheading:10455888-Mice, Inbred BALB C,
pubmed-meshheading:10455888-Microfilament Proteins,
pubmed-meshheading:10455888-Muscle Proteins,
pubmed-meshheading:10455888-Proto-Oncogene Proteins c-bcl-2,
pubmed-meshheading:10455888-Stomach Neoplasms,
pubmed-meshheading:10455888-Tumor Cells, Cultured,
pubmed-meshheading:10455888-Tumor Suppressor Protein p53
|
|
pubmed:year |
1999
|
|
pubmed:articleTitle |
Inhibition of gastric cancer by camptothecin involves apoptosis and multiple cellular pathways.
|
|
pubmed:affiliation |
Department of Surgery, University of Texas Medical Branch, Galveston 77555-0533, USA.
|
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't
|
